

**Xermelo**  
**Effective 09/01/2021**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Telotristat etiprate is a prodrug of telotristat, which is a tryptophan hydroxylase inhibitor. Used in combination with a somatostatin analog (SSA) for treatment of diarrhea associated with carcinoid syndrome in adults that SSA therapy alone has shown inadequate

### Coverage Guidelines

Authorization may be granted for members currently being treated with Xermelo, except when the medication has been obtained through physician samples or manufacturer's assistance program.

OR

Authorization may be granted if the member meets all following criteria and documentation has been submitted:

1. The member is at least 18 years of age
2. The member has diagnosis of carcinoid syndrome diarrhea
3. The member has had an inadequate response to somatostatin analog (SSA) therapy
4. Xermelo will be used in combination with SSA therapy

### Limitations

1. Approvals will be granted for 12 months
2. The following quantity limits apply:

Xermelo 250mg	90 tablets per 30 days
---------------	------------------------

## References

1. Xermelo (telotristat ethyl) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; October 2020
2. Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. *J Clin Oncol*. 2017;35(1):14-23.[PubMed 27918724]

## Review History

02/20/2019 – Approved by P&T

01/20/2021 – Reviewed by P&T. Effective 09/01/2021.

